Familial Hypercholesterolemia: Do HDL Play a Role?

Lipoprotein Metabolism in Familial Hypercholesterolemia

(2021) Kévin Chemello et al.   JOURNAL OF LIPID RESEARCH

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia

(2021) Joan Carles Escolà-Gil et al.   Current Atherosclerosis Reports

High-Density Lipoproteins Are the Main Carriers of PCSK9 in the Circulation

(2020) Sean A. Burnap et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight from Mouse Models

(2020) Lidia Cedo et al.   CIRCULATION RESEARCH

Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia

(2020) Etienne Khoury et al.   Journal of Clinical Medicine

Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia

(2019) Sofía Perez-Calahorra et al.   ATHEROSCLEROSIS

Human high-density lipoprotein microtranscriptome is unique and suggests an extended role in lipid metabolism

(2019) Véronique Desgagné et al.   Epigenomics

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia

(2019) Ilse K. Luirink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop

(2019) Annabelle Rodriguez et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation

(2019) Roberto Scicali et al.   Scientific Reports

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register

(2018) S.E. Humphries et al.   ATHEROSCLEROSIS

Predicting cardiovascular disease in familial hypercholesterolemia

(2018) Martine Paquette et al.   CURRENT OPINION IN LIPIDOLOGY

The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications

(2018) Nathan Wong et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Altered HDL Remodeling and Functionality in Familial Hypercholesterolemia

(2018) Lídia Cedó et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene

(2018) Muhammad Idrees et al.   GENETICS AND MOLECULAR BIOLOGY

Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins

(2018) Debi K. Swertfeger et al.   Journal of Clinical Lipidology

Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis

(2018) Leo E. Akioyamen et al.   Journal of Clinical Lipidology

Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol

(2018) Eline H. van den Berg et al.   JOURNAL OF LIPID RESEARCH

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDL cholesterol concentration or HDL function: which matters?

(2017) Philip J. Barter et al.   EUROPEAN HEART JOURNAL

Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs

(2017) Teresa Padró et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

(2017) Robert S. Rosenson et al.   Nature Reviews Cardiology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDL abnormalities in familial hypercholesterolemia: Focus on biological functions

(2017) Shiva Ganjali et al.   PROGRESS IN LIPID RESEARCH

Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials

(2017) Li Jun Qian et al.   Scientific Reports

Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia

(2016) Pãmela R.S. Silva et al.   ATHEROSCLEROSIS

Familial hypercholesterolaemia: cholesterol efflux and coronary disease

(2016) Jorie Versmissen et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

The p.Leu167del Mutation inAPOEGene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes

(2016) Ana Cenarro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis

(2016) Hala Hussein et al.   Journal of Clinical Lipidology

ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia

(2016) Judit Cubedo et al.   JOURNAL OF LIPID RESEARCH

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

(2016) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statins in Familial Hypercholesterolemia

(2016) Joost Besseling et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

(2016) Nicola Ferri et al.   Translational Research

Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease

(2016) Simon-Pierre Guay et al.   Epigenomics

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia

(2016) Bin Li et al.   Oncotarget

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

(2015) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Dysfunctional HDL and atherosclerotic cardiovascular disease

(2015) Robert S. Rosenson et al.   Nature Reviews Cardiology

Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia

(2014) Simon-Pierre Guay et al.   Epigenetics

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

(2014) Anand Rohatgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA methylation variations at CETP and LPL gene promoter loci: New molecular biomarkers associated with blood lipid profile variability

(2013) S.P. Guay et al.   ATHEROSCLEROSIS

Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia

(2013) Lilton R.C. Martinez et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

ABCA1gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia

(2012) Simon-Pierre Guay et al.   Epigenetics

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

(2012) Alexina Orsoni et al.   JOURNAL OF LIPID RESEARCH

High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events

(2012) Rachel H. Mackey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration

(2012) Simon-Pierre Guay et al.   Epigenomics

Atheroprotective Reverse Cholesterol Transport Pathway Is Defective in Familial Hypercholesterolemia

(2011) Natacha Bellanger et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation

(2011) David Hine et al.   IUBMB LIFE

The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations

(2011) Lynn Htet Htet Aung et al.   Lipids in Health and Disease

MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins

(2011) Kasey C. Vickers et al.   NATURE CELL BIOLOGY

Dyslipidemia of Mothers With Familial Hypercholesterolemia Deteriorates Lipids in Adult Offspring

(2010) Anouk van der Graaf et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Missing heritability and strategies for finding the underlying causes of complex disease

(2010) Evan E. Eichler et al.   NATURE REVIEWS GENETICS

Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents

(2009) A. Baass et al.   CLINICAL CHEMISTRY

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

(2009) Marianne Abifadel et al.   HUMAN MUTATION

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM